Incyte Corporation, Wilmington, has earned a $50 million milestone payment from Eli Lilly and Company based on the formal initiation of the rheumatoid arthritis RA Phase III program for baricitinib.
The Phase III program is being conducted by Lilly as part of the exclusive agreement for baricitinib.
Four Phase III studies are planned, which will investigate the safety and effectiveness of baricitinib 2 mg and 4 mg once daily in patients with active rheumatoid arthritis. Patients completing any of the four studies will be eligible for enrollment in a fifth study, a long-term extension.
Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs for cancer and inflammation. For additional information, visit www.incyte.com.